Abstract
Apoptosis is a genetically programmed process of controlled and orderly cell suicide, which is critical for multicellular organisms during development and tissue homeostasis. In cancer, the ratio of apoptosis to cell division is altered, resulting in a net gain of malignant tissue. Tumor cells may acquire resistance to apoptosis by the expression of anti-apoptotic proteins, or by the down-regulation or mutation of pro-apoptotic mediators. In the classic pathway of apoptosis, this process is primarily coordinated by activation of caspases. Decreased expression of caspases inversely correlates with the aggressiveness of cancer. Increased activity of caspases renders cancer cells susceptible to chemoradiotherapeutic modalities. Thus, caspase activity is pivotal in carcinogenesis. The functions of activated caspases are inhibited by the binding of inhibitors of apoptosis (IAPs). The function of IAPs is regulated by pro-apoptotic protein Second Mitochondria-Derived Activator of Caspases (Smac) or Direct IAP Binding Protein with low isoelectric point, pI (DIABLO). Induction of apoptosis leads to increased mitochondrial permeability to Smac/DIABLO, which adheres to IAPs inhibiting their caspase-binding activity. The role of Smac/DIABLO, therefore, may have significant diagnostic and therapeutic features in carcinogenesis. The role of Smac/DIABLO in colorectal carcinogenesis is ill defined. Data continues to accumulate to suggest that decreased levels of Smac/DIABLO may be important in chemoradiation-resistance to apoptosis in advanced colon cancer. The aim of this review is to provide the available evidence of the role of Smac/DIABLO in colon carcinogenesis.
Keywords: AIF, Apoptosis, IAP, cancer, cancer chemotherapy, colon cancer, mitochondria, Smac/DIABLO
Anti-Cancer Agents in Medicinal Chemistry
Title: Smac/DIABLO and Colon Cancer
Volume: 7 Issue: 4
Author(s): Y.M. Anguiano-Hernandez, A. Chartier and S. Huerta
Affiliation:
Keywords: AIF, Apoptosis, IAP, cancer, cancer chemotherapy, colon cancer, mitochondria, Smac/DIABLO
Abstract: Apoptosis is a genetically programmed process of controlled and orderly cell suicide, which is critical for multicellular organisms during development and tissue homeostasis. In cancer, the ratio of apoptosis to cell division is altered, resulting in a net gain of malignant tissue. Tumor cells may acquire resistance to apoptosis by the expression of anti-apoptotic proteins, or by the down-regulation or mutation of pro-apoptotic mediators. In the classic pathway of apoptosis, this process is primarily coordinated by activation of caspases. Decreased expression of caspases inversely correlates with the aggressiveness of cancer. Increased activity of caspases renders cancer cells susceptible to chemoradiotherapeutic modalities. Thus, caspase activity is pivotal in carcinogenesis. The functions of activated caspases are inhibited by the binding of inhibitors of apoptosis (IAPs). The function of IAPs is regulated by pro-apoptotic protein Second Mitochondria-Derived Activator of Caspases (Smac) or Direct IAP Binding Protein with low isoelectric point, pI (DIABLO). Induction of apoptosis leads to increased mitochondrial permeability to Smac/DIABLO, which adheres to IAPs inhibiting their caspase-binding activity. The role of Smac/DIABLO, therefore, may have significant diagnostic and therapeutic features in carcinogenesis. The role of Smac/DIABLO in colorectal carcinogenesis is ill defined. Data continues to accumulate to suggest that decreased levels of Smac/DIABLO may be important in chemoradiation-resistance to apoptosis in advanced colon cancer. The aim of this review is to provide the available evidence of the role of Smac/DIABLO in colon carcinogenesis.
Export Options
About this article
Cite this article as:
Y.M. Anguiano-Hernandez , A. Chartier and S. Huerta , Smac/DIABLO and Colon Cancer, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/187152007781058631
DOI https://dx.doi.org/10.2174/187152007781058631 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Synthesis and Anti-thyroid Cancer Effect of Iodo-chrysin Derivatives
Medicinal Chemistry Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Efficacy of Bacteria in Cancer Immunotherapy: Special Emphasis on the Potential of Mycobacterial Species
Clinical Cancer Drugs Editorial [Hot Topic: Novel Non-Cytotoxic Approaches For Cancer Therapy: Potential Targets and Pathways Amenable to Single Agent Multimodal Therapeutic Approaches (Guest Editor: Andrew Mazar)]
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Cancer Drug Targets Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Dedication to Professor Tony Dodi
Current Cancer Therapy Reviews Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation
Current Drug Safety Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan
Drug Metabolism Letters PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions
Current Drug Delivery Extracellular Signals for Guiding Mesenchymal Stem Cells Osteogenic Fate
Current Stem Cell Research & Therapy Combination Therapy for the Treatment of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Methods for Analysis of Free Radicals in Cigarette Smoke
Mini-Reviews in Organic Chemistry Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?
Current Vascular Pharmacology Recent Progress on the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers
Current Topics in Medicinal Chemistry Recent Patents for Predictive and Prognostic Biomarkers in Non-Small-Cell Lung Cancer
Recent Patents on Biomarkers Relevance of an Academic GMP Pan-European Vector Infra-Structure (PEVI)
Current Gene Therapy